856106-63-3

Usage

Uses

Used in Pharmaceutical Industry:
2,4-dihydroxy-5-iodobenzoic acid is used as an antibacterial agent for its potential to treat bacterial infections. Its unique structure with two hydroxyl groups and an iodine atom contributes to its biological activity against bacteria.
Used in Cosmetic Industry:
2,4-dihydroxy-5-iodobenzoic acid is used as a natural preservative for its antioxidant properties, helping to prevent spoilage and extend the shelf life of cosmetic products.
Used in Food Industry:
2,4-dihydroxy-5-iodobenzoic acid is used as a natural preservative for its potential to prevent spoilage and extend the shelf life of food products, thanks to its antibacterial properties.

Upstream product

• 60-29-7 diethyl ether 
• 89-86-1 4-hydroxysalicylic acid 
• 7790-99-0 Iodine monochloride 

Downstream Products

• 1404435-76-2 2-(4-(carboxymethoxy)phenyl)-3-((3-chlorophenyl)ethynyl)-6-hydroxybenzofuran-5-carboxylic acid 
• 1441379-99-2 methyl 2-(4-(6-((3-chlorophenyl)ethynyl)-2,2-dimethyl-4-oxo-4H-[1,3]dioxino[5,4-f ]benzofuran-7-yl)phenoxy)acetate 
• 1441379-88-9 methyl 2-(4-(6-iodo-2,2-dimethyl-4-oxo-4H-[1,3]dioxino[5,4-f ]-benzofuran-7-yl)phenoxy)acetate 
• 1441379-76-5 methyl 2-(4-((7-methoxy-2,2-dimethyl-4-oxo-4H-benzo[d][1,3]dioxin-6-yl)ethynyl)-phenoxy)acetate 
• 1404435-75-1 2-(3-(carboxymethoxy)phenyl)-3-((3-chlorophenyl)ethynyl)-6-hydroxybenzofuran-5-carboxylic acid 
• 1441379-94-7 methyl 2-(3-(6-((3-chlorophenyl)ethynyl)-2,2-dimethyl-4-oxo-4H-[1,3]dioxino[5,4-f ]benzofuran-7-yl)phenoxy)acetate 
• 1441379-82-3 methyl 2-(3-(6-iodo-2,2-dimethyl-4-oxo-4H-[1,3]dioxino[5,4-f ]-benzofuran-7-yl)phenoxy)acetate 
• 1441379-70-9 methyl 2-(3-((7-methoxy-2,2-dimethyl-4-oxo-4H-benzo[d][1,3]dioxin-6-yl)ethynyl)phenoxy)acetate 
• 1404435-65-9 3-((3-(carboxymethoxy)phenyl)ethynyl)-6-hydroxy-2-(4-(trifluoromethoxy)phenyl)benzofuran-5-carboxylic acid 
• 1404435-64-8 6-hydroxy-3-(thiophen-3-ylethynyl)-2-(4-(trifluoromethoxy)-phenyl)benzofuran-5-carboxylic acid 
• 1404435-63-7 3-((3,4-dichlorophenyl)ethynyl)-6-hydroxy-2-(4-(trifluoromethoxy)phenyl)benzofuran-5-carboxylic acid 
• 1404435-62-6 3-((3-chlorophenyl)ethynyl)-6-hydroxy-2-(4-(trifluoromethoxy)-phenyl)benzofuran-5-carboxylic acid 
• 1441379-19-6 methyl 2-(3-((2,2-fimethyl-4-oxo-7-(4-(trifluoromethoxy)phenyl)-4H-[1,3]dioxino[5,4-f ]benzofuran-6-yl)ethynyl)phenoxy)acetate 
• 1441379-13-0 2,2-dimethyl-6-(thiophen-3-ylethynyl)-7-(4-(trifluoromethoxy)-phenyl)-4H-[1,3]dioxino[5,4-f ]benzofuran-4-one 

Relevant academic research and scientific papers

A potent and selective small-molecule inhibitor for the lymphoid-specific tyrosine phosphatase (LYP), a target associated with autoimmune diseases

Lymphoid-specific tyrosine phosphatase (LYP), a member of the protein tyrosine phosphatase (PTP) family of signaling enzymes, is associated with a broad spectrum of autoimmune diseases. Herein we describe our structure-based lead optimization efforts with

Discovery and evaluation of novel inhibitors of mycobacterium protein tyrosine phosphatase B from the 6-hydroxy-benzofuran-5-carboxylic acid scaffold

Mycobacterium tuberculosis (Mtb) protein tyrosine phosphatase B (mPTPB) is a virulence factor secreted by the pathogen and mediates mycobacterial survival in macrophages by targeting host cell immune responses. Consequently, mPTPB represents an exciting n

TYROSINE PHOSPHATASE INHIBITORS AND USES THEREOF TO MODULATE THE ACTIVITY OF LYP

A variety of benzofurans and indole derivatives some with an acetyl linker are disclosed herein. These compounds are not highly charged at physiological pH and have good bioavailability characteristics. These compounds exhibit selective or at least preferential affinity for the active sites of various sub-sets of protein tyrosine phosphatases. The lymphoid- specific tyrosine phosphatase (Lyp) has received enormous attention because of the finding that a single- nucleotide polymorphism (SNP) in the gene (PTPN22) encoding Lyp is associated with several autoimmune diseases, including type I diabetes. Many of these compounds and pharmaceutically acceptable salts thereof are novel therapeutic compounds useful for the treatment of various diseases including a number of autoimmune diseases.

Design, synthesis, and structure - Activity relationships for chimeric inhibitors of Hsp90

(Chemical Equation Presented) Inhibition of the 90 kDa heat shock protein (Hsp90) family of molecular chaperones represents a promising new chemotherapeutic approach toward the treatment of several cancers. Previous studies have demonstrated that the natural products, radicicol and geldanamycin, are potent inhibitors of the Hsp90 N-terminal ATP binding site. The cocrystal structures of these molecules bound to Hsp90 have been determined, and through molecular modeling and superimposition of these ligands, hybrids of radicicol and geldanamycin have been designed. A series of macrocylic chimeras of radicicol and geldanamycin and the corresponding seco-agents have been prepared and evaluated for both antiproliferative activity and their ability to induce Hsp90-dependent client protein degradation.